Navigation Links
Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
Date:12/5/2007

s decision. The decision is unrelated to the on-going NTI 0303 Phase III study, which is now close to completing recruitment and is expected to reach final data analysis and conclusions in 2008.

"XERECEPT(R) is an investigational new drug that may present a steroid- sparing alternative to dexamethasone. Dexamethasone is the only treatment currently available for PBE, but this corticosteroid is associated with debilitating side effects, including vision problems, muscle and bone loss, irritability, impaired wound healing and opportunistic infections."

NTI sold the worldwide rights and assets related to XERECEPT to Celtic Pharma in November 2005. NTI is entitled to receive milestone payments upon the achievement of certain regulatory objectives and, if XERECEPT, is approved for commercial sale, NTI is entitled to receive profit-sharing payments on sales in the United States and royalties on sales elsewhere in the world.

About Neurobiological Technologies, Inc.

NTI is specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late- stage clinical trials for central nervous system conditions. NTI is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke. For more information, please visit the company's website: http://www.ntii.com.

Forward-Looking Statements:

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including the limited control we have over the development and commercialization of XERECEPT, as well as other risks detailed from time to time in our Annual Report of Form 10-K and other filings with the Securities and Exchange Commission. Actual results may differ materially from those project
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... -- A decade-long JDRF-funded study led by the Institute ... Germany , is providing a deeper understanding of ... type 1 diabetes (T1D), highlighting the importance of pre-diabetes ... "Seroconversion to Multiple Islet Autoantibodies and Risk of Progression ... The Journal of the American Medical Association . ...
(Date:6/19/2013)... , June 19, 2013 The Physician-Patient Alliance for ... fatigue. The need to urgently address this issue ... Sentinel Event Alert #50 , "Medical device alarm safety in ... between January 2008 and June 2012, there were 98 alarm ... in death (82%) , 13 resulted in permanent loss ...
(Date:6/19/2013)... , June 19, 2013  Caradigm today ... a solution designed to help healthcare organizations ... data while supporting their compliance with data ... represents a milestone in the delivery of ... capabilities for health systems. ...
Breaking Medicine Technology:New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 2New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 3Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Caradigm Provisioning Helps Healthcare Organizations Improve Clinical Efficiency, Manage Risk 2Caradigm Provisioning Helps Healthcare Organizations Improve Clinical Efficiency, Manage Risk 3
... Cempra Pharmaceuticals, a developer of differentiated antibiotics, ... (IV) solithromycin demonstrates excellent tolerability and ... up to 800 mg.  Oral administration of solithromycin ... 1 studies.  The presentation will be at the ...
... Covance Inc. (NYSE: CVD ) today announced that ... Tuesday, May 10, 2011 at 3:00 p.m. ET.  Investors may ... .  In order to register and download any necessary software, ... headquarters in Princeton, New Jersey, is one of the world,s ...
Cached Medicine Technology:Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 3Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 4Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 5Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 6Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 7Covance to Present at Baird's 2011 Growth Stock Conference 2
(Date:6/19/2013)... Dental professionals are increasingly monitoring end tidal carbon ... sedation, a patient’s breathing depth and rate decrease. ... to update its guidelines to require etCO2 monitoring, or ... to increase safety in procedures. This amendment to Section ... effect July 1. , The Oregon Board of ...
(Date:6/19/2013)... Moffitt Cancer Center and colleagues at Louisiana State University ... that require immediate therapy. It relies on understanding the ... is to better predict a prostate cancer,s aggressiveness to ... published in the online journal PLOS ONE ... accounts for 20 percent of all cancers and 9 ...
(Date:6/19/2013)... Ariz. (PRWEB) June 19, 2013 PREFERRED ... WellCare of Arizona to offer a new ... Maricopa, Pima, La Paz, Yavapai and Mohave, Arizona counties. ... Mohave counties were effective January 1, 2013 and Maricopa ... 2014. , WellCare, Inc., the parent company of WellCare ...
(Date:6/19/2013)... 19, 2013 DiscountFurnaceFilter.com, the number one solution ... the 5-2-1 Compressor Saver kit at an exceptional price. The ... aids the air conditioning unit during start up, saving wear ... compressor or unit burn out. , The 5-2-1 Compressor ... air conditioner uses less power to start and drastically reduces ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Brightree LLC ... business management software solutions for the post-acute care industry, has ... - on the Healthcare Informatics 100 (HCI 100) ... companies in the U.S. in terms of revenue during the ... an average rate of 85% annually, and the company has ...
Breaking Medicine News(10 mins):Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 3Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2Health News:PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3
... 1 issue of the journal Sleep indicates that ... remain vigilant and attentive deteriorated significantly after losing less than ... study suggests that even moderate reductions in sleep duration can ... the academic performance of children with ADHD. Results of ...
... This release is also available in Chinese on ... Despite the absence of Medicare coverage, hospital use of computed ... the rise, according to a study in the March issue of ... www.jacr.org ). Colorectal cancer is the second leading cause of ...
... dissection, the current standard surgical treatment for localized non-small ... stage cases , according to a study published in the ... (JTO), the official journal of the International Association for the ... is very low in early-stage cancers with a maximum standard ...
... adhesive patches is at the center of an agreement ... arm of Italian pharmaceutical leader Zambon Co., SpA, to ... ways to deliver oral medications directly to a targeted ... sponsored research agreement between Zcube and UCSF, but is ...
... By Serena Gordon HealthDay Reporter , MONDAY, ... fears soaring as quickly as a child,s rapidly rising temperature. ... Pediatrics (AAP) attempts to allay those fears by reminding parents ... against illness, and that lowering a fever may actually prolong ...
... , MONDAY, Feb. 28 (HealthDay News) -- Many American women ... treatment was tied to higher breast cancer risk. A sharp ... after. However, a new study suggests that the 2002-2003 ... continue through 2007. The data suggests that the drop ...
Cached Medicine News:Health News:Moderate sleep loss impairs vigilance and sustained attention in children with ADHD 2Health News:Moderate sleep loss impairs vigilance and sustained attention in children with ADHD 3Health News:Hospital use of virtual colonoscopy is on the rise, study suggests 2Health News:Lymph node dissection is not essential in small screen-detected lung cancers, new research shows 2Health News:UCSF collaborates with Zcube to develop new ways to deliver drugs 2Health News:Kids' Fevers May Not Always Need Treatment 2Health News:Kids' Fevers May Not Always Need Treatment 3Health News:Drop in Breast Cancer Among White Women May Have Stalled 2
Worn by many professional athletes, EpiTrain is our most popular elbow support....
... combines the therapeutic benefits of controlled compression ... to minimize pain. The cuff is anatomically ... maximum cryotherapy. The Elbow Cryo/Cuff is available ... a pediatric size.,All Cryo/Cuffs can be ordered ...
... The Cryo/Cuff for Walking Brace is designed ... to the Aircast PneumaticWalker™ (sold separately). When ... cold water, the cuff surrounds the foot ... to minimize hemarthrosis, swelling, and pain.,All Cryo/Cuffs ...
... support helps reduce swelling and minimize pain while ... easy to apply - it slips on like ... into shoes. It features bilateral spiral stays ... support and stability. This is an excellent ...
Medicine Products: